文献速递浆细胞疾病造血干细胞移植与细胞治疗

KRd与VRd诱导方案在新诊断多发性骨髓瘤自体移植前的比较

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.
PubMed 文献 · Br J Haematol · 2026-07-06

该单中心回顾性研究分析了1129例接受KRd(n=364)或VRd(n=765)诱导后行自体造血干细胞移植的新诊断多发性骨髓瘤患者。KRd组移植前完全缓解率和≥非常好的部分缓解率更高,移植前MRD阴性率更高,中位无进展生存期更长(62.2 vs 48.7个月),但总生存期无差异。

要点

  • KRd较VRd诱导获得更深缓解:移植前CR 23% vs 16%,≥VGPR 71% vs 61%。
  • KRd组中位PFS 62.2个月,VRd组48.7个月,HR 0.74(95%CI 0.59-0.93),P=0.009。
  • 中位OS KRd组未达到,VRd组122.7个月,HR 0.86(95%CI 0.59-1.25),P=0.43。

核心结论

  • KRd诱导较VRd获得更深缓解并改善PFS,但OS无差异。

研究设计与样本

  • 单中心回顾性分析2006-2021年1129例接受KRd(n=364)或VRd(n=765)诱导后行自体移植的新诊断多发性骨髓瘤患者。

主要发现

  • KRd组移植前CR率23%、≥VGPR率71%,VRd组分别为16%、61%(p=0.002)。
  • KRd组移植后最佳≥CR率71%,VRd组60%(p=0.001)。
  • KRd组移植前MRD阴性率49%,VRd组42%(p=0.027)。
  • 中位随访38.6个月,KRd组中位PFS 62.2个月,VRd组48.7个月(HR 0.74,95%CI 0.59-0.93,p=0.009)。
  • 中位OS KRd组未达到,VRd组122.7个月(HR 0.86,95%CI 0.59-1.25,p=0.43)。

关键数值与推荐

  • 逆概率加权多变量分析中KRd仍与PFS改善相关(HR 0.76,95%CI 0.60-0.97,p=0.025),OS无差异。
  • PFS获益在标危、年轻、男性及合并症较少的患者中更明显。

临床怎么用

  • 对于适合移植的新诊断多发性骨髓瘤患者,KRd诱导可能带来更深缓解和更长PFS。

局限性

  • 回顾性单中心设计,KRd组高危细胞遗传学和晚期R2-ISS分期比例更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bortezomib, lenalidomide and dexamethasone (VRd) and carfilzomib, lenalidomide and dexamethasone (KRd) regimens have been widely used for induction in transplant-eligible newly diagnosed multiple myeloma (NDMM), yet direct comparisons between these regimens have been limited and inconsistent. We retrospectively analysed 1129 NDMM patients who received KRd (n = 364) or VRd (n = 765) before upfront autologous haematopoietic stem cell transplantation at a single-centre between 2006 and 2021. KRd-treated patients more often had high-risk cytogenetics and advanced Second revision of the International Staging System (R2-ISS) stage. Pretransplant complete response (CR) and ≥very good partial response (VGPR) rates were higher with KRd (23% and 71%) than VRd (16% and 61%; p = 0.002), with superior best post-transplant ≥CR (71% vs. 60%; p = 0.001) and higher pretransplant measurable residual disease (MRD) negativity (49% vs. 42%; p = 0.027). After a median follow-up of 38.6 months, median progression-free survival (PFS) was 62.2 versus 48.7 months (hazard ratio [95% confidence interval] 0.74 [0.59-0.93], p = 0.009) and median overall survival (OS) was not reached versus 122.7 months (0.86 [0.59-1.25], p = 0.43) for KRd and VRd respectively. In inverse probability-weighted multivariable analysis, KRd remained associated with improved PFS (0.76 [0.60-0.97], p = 0.025), with no OS difference. The PFS benefit was most pronounced in standard-risk, younger and male patients, and those with fewer comorbidities. Overall, KRd induction led to deeper responses and improved PFS compared with VRd.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Marcoux C, Milton DR, Tanner MR, et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma. Br J Haematol. 2026. PMID: 42403116. doi:10.1111/bjh.70642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。